

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of

Application Number

07/310,252

Filed

Feb. 13, '89

Group Art Unit

185

Examiner

Feisee

Paper No.

20

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☒ (A) referred to in United States Patent Number 5,585,089, column 63.
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Joshua Woods

Signature

Joshua Woods

Typed or printed name

11/18/97

Date

FOR OFFICIAL USE ONLY

Approved by: 11/18/97

(Initials)

Unit:

FIII

[54] HUMANIZED IMMUNOGLOBULINS

[75] Inventors: Cary L. Queen, Los Altos; Man Sung Co, Cupertino; William P. Schneider, Mountain View; Nicholas F. Landolt, Milpitas; Kathleen L. Coelingh, San Francisco; Harold E. Selick, Belmont, all of Calif.

[73] Assignee: Protein Design Labs, Inc., Mountain View, Calif.

[21] Appl. No.: 487,200

[22] Filed: Jun. 7, 1995

Related U.S. Application Data

[63] Continuation of Ser. No. 634,278, Dec. 19, 1990, Pat. No. 5,530,101, which is a continuation-in-part of Ser. No. 590,274, Sep. 28, 1990, abandoned, and Ser. No. 310,252, Feb. 13, 1989, abandoned, which is a continuation-in-part of Ser. No. 290,975, Dec. 28, 1988, abandoned.

[51] Int. Cl.⁶ A61K 39/395

[52] U.S. Cl. 530/387.3; 530/388.22; 424/133.1; 424/143.1

[58] Field of Search 530/387.3, 388.22; 424/133.1, 143.1

[56] References Cited

U.S. PATENT DOCUMENTS

4,578,335	3/1986	Urdal et al.	530/351
4,816,397	3/1989	Boas et al.	435/68
4,816,565	3/1989	Honjo et al.	435/69.1
4,816,567	3/1989	Cabilly et al.	530/387
4,845,198	7/1989	Urdal et al.	530/387
4,867,973	9/1989	Goers et al.	424/85.91
5,198,359	3/1993	Taniguchi et al.	435/252.3
5,225,539	7/1993	Winter	530/387.3
5,476,786	12/1995	Huston et al.	435/252.33

FOREIGN PATENT DOCUMENTS

0 120 694	10/1984	European Pat. Off.
0171496	2/1986	European Pat. Off.
0173494	3/1986	European Pat. Off.
0184187	6/1986	European Pat. Off.
0256654	7/1987	European Pat. Off.
0 239 400	9/1987	European Pat. Off.
0239400	9/1987	European Pat. Off.
0266663	6/1988	European Pat. Off.
0 323 806	7/1989	European Pat. Off.
0 328 404	8/1989	European Pat. Off.
0 365 209	4/1990	European Pat. Off.
0 365 997	5/1990	European Pat. Off.
0 125 023	6/1991	European Pat. Off.
0460167	12/1991	European Pat. Off.
2188941	10/1987	United Kingdom
8928874	12/1989	United Kingdom
WO 86/05513	9/1986	WIPO
WO 87/02671	5/1987	WIPO
WO 88/09344	12/1988	WIPO
WO 89/01783	3/1989	WIPO
91/09967	7/1991	WIPO

OTHER PUBLICATIONS

- 1 Groves et al. Hybridoma vol. 6 (1) 1987 71.
- 2 Chothia, C. and Lesk, A.M., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987).
- 3 Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).
- 4 Junghans et al., *Cancer Res.*, 50:1495-1502 (1990).
- 5 Kupiec-Weglinski et al., *Proc. Natl. Acad. Sci.*, 83:2624 (1986).
- 6 Maeda et al., "Construction of reshaped human antibodies with HIV-neutralizing activity," *Hum. Antibod. Hybrid.*, 2:124-134 (1991).
- 7 Morrison et al., "Chimeric human antibody molecules: Mouse antigen binding-domains with human constant region domains," *Proc. Natl. Acad. Sci.*, 81:6851-6859 (1984).
- 8 Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies," *Science*, 229:1202-1207 (1985).
- 9 Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).
- 10 Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).
- 11 Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen," *J. Immunol.*, 137:1066-1074 (1986).
- 12 Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," *Science*, 239:1534-1536 (1988).
- 13 Amit et al., *Science*, 233, 747-753 (1986).
- 14 Cheetham, *Protein Engineering*, 2(3), 170-172 (1988).

(List continued on next page.)

Primary Examiner—Lila Feisec

Assistant Examiner—Julie B. Reeves

Attorney, Agent, or Firm—Townsend & Townsend & Crew

[57]

ABSTRACT

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

OTHER PUBLICATIONS

- 15 Chothia et al., *J. Mol. Biol.*, 186, 651-663 (1985).
- 16 Chothia et al., *Nature*, 342, 877-883 (1989).
- 17 Chothia et al., *Science*, 233, 755-758 (1986).
- 18 Chothia and Lesk, *EMBO J.*, 5, 823-826 (1986).
- 19 Colman et al., *Nature*, 326, 358-362 (1987).
- 20 Davies et al., *Ann. Rev. Immunol.*, 1, 87-117 (1983).
- 21 Davies et al., *J. Biol. Chem.*, 263(22), 10541-10544 (1988).
- 22 Epp et al., *Eur. J. Biochem.*, 45, 513-524 (1974).
- 23 Feldmann et al., *Mol. Immunol.*, 18, 683-698 (1981).
- 24 Kabat, *J. Immunol.*, 125, 961-969 (1980).
- 25 Lesk and Chothia, *J. Mol. Biol.*, 160, 325-342 (1982).
- 26 Padlan, *Mol. Immunol.*, 31, 169-217 (1994).
- 27 Palm et al., *Hoppe Seyler's Z. Physiol. Chem.*, 354(12), 1651-1654 (1973).
- 28 Palm et al., *Hoppe Seyler's Z. Physiol. Chem.*, 356, 167-191 (1975).
- 29 Panka et al., *PNAS-USA*, 85, 3080-3084 (1988).
- 30 Roberts et al., *Nature*, 328, 731-734 (1987).
- 31 Saul et al., *J. Biol. Chem.*, 253(2), 585-597 (1978).
- 32 Sheriff et al., *PNAS-USA*, 84, 8075-8079 (1987).
- 33 Stanford and Wu, *J. Theor. Biol.*, 88, 421-439 (1981).
- 34 Tramontano et al., *J. Mol. Biol.*, 215, 175-182 (1990).
- 35 Verhoeyen et al., *BioEssays*, 8(2), 74-78 (1988).
- 36 Waldmann et al., *Cancer Research*, 45, 4559s-4562s (1985).
- 37 Wu and Kabat, *J. Exp. Med.*, 132, 211-250 (1970).
- 38 Better et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," *Science*, 240:1041-1043 (1988).
- 39 Bird et al., "Single-Chain Antigen-Binding Proteins," *Science*, 242:423-426 (1988).
- 40 Boulianne et al., "Production of functional chimeric mouse/human antibody," *Nature*, 312:643-646 (1984).
- 41 Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy," *Proc. Natl. Acad. Sci.*, 89:4285-4289 (1992).
- 42 Co et al., "Humanized antibodies for antiviral therapy," *Proc. Natl. Acad. Sci.*, 88:2869-2873 (1991).
- 43 Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," *J. Immunol.*, 148:1149-1154 (1992).
- 44 Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expansion of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nuc. Acids. Res.*, 19:2471-2476 (1991).
- 45 Ellison et al., "The nucleotide sequence of a human immunoglobulin α (gamma)₁ gene," *Nucleic Acids Res.*, 10:4071-4082 (1982).
- 46 Farrar, J., "The biochemistry, biology, and the role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," *Immunol. Rev.*, 63:129-166 (1982).
- 47 Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," *J. Mol. Biol.*, 224:487-499 (1992).
- 48 Gorman et al., "Reshaping a therapeutic CD4 antibody," *Proc. Natl. Acad. Sci.*, 88:4181-4185 (1991).
- 49 Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and its Cellular receptor," *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York, pp. 283-301 (1986).
- 50 Hale et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H," *Lancet*, Dec. 17, 1988, pp. 1394-1399.
- 51 Hieter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J. Region Genes Conserve Homology in Functional Segments," *Cell*, 22:197-207 (1980).
- 52 Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*," *Proc. Nat. Acad. Sci. USA*, 85:5879-5883 (1988), *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York, p. 283, (1986).
- 53 Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," *Protein Eng.*, 4:773-783 (1991).
- 54 Kirkman et al., *J. Exp. Med.*, 162:358 (1985).
- 55 Leonard et al., "The human receptor for T-cell growth factor," *J. Biol. Chem.*, 260:1872-1880 (1985).
- 56 Liu et al., "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," *Gene*, 54:33-40 (1987).
- 57 Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," *Proc. Natl. Acad. Sci.*, 86:10029-10033 (1989).
- 58 Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," *Eur. J. Immunol.*, 21:2717-2725 (1991).
- 59 Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," *J. Exp. Med.*, 175:217-225 (1992).
- 60 Sharon et al., "Expression of a V_HC_K chimaeric protein in mouse myeloma cells," *Nature*, 309:364-367 (1984).
- 61 Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human $\alpha\beta$ T cell receptor," *J. Immunol.*, 147:4366-4373 (1991).
- 62 Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," *Nature*, 314:452-454 (1985).
- 63 Tan et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells," *J. Immunol.*, 135:3564-3567 (1985).
- 64 Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," *BioTechnology*, 9:26-271 (1991).
- 65 Uchiyama et al., "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells," *J. Immunol.*, 126:1393-1397 (1981).
- 66 Vitetta et al., "Redesigning nature's Poisons to Create Anti-Tumor reagents," *Science*, 238:1098-1104 (1987).
- 67 Waldmann, T.A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes," *Science*, 232:727-732 (1986).
- 68 Woodle et al., "Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression," *J. Immunol.*, 148:2756-2763 (1992).